Product
PEGPH20
4 clinical trials
4 indications
Indication
Pancreatic adenocarcinomaIndication
Gastric AdenocarcinomaIndication
Pancreatic CancerIndication
Pancreatic Ductal AdenocarcinomaClinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)Status: Active (not recruiting), Estimated PCD: 2024-08-24
Clinical trial
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2019-04-01
Clinical trial
Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01